Table 1.
Publication | Age/sex | Location of metastasis | Treatment prior to CNS disease | Treatment for CNS metastasis | Time to CNS disease after Primary Dx | Survival after CNS metastasis | Overall survival |
---|---|---|---|---|---|---|---|
Kroll et al. [13]a | 48 M | Brain | ? | ? | ? | ? | ? |
Kroll et al. [13]a | 70 M | Brain | ? | ? | ? | ? | ? |
Kroll et al. [13]a | 72 F | Meninges | ? | ? | ? | ? | ? |
Wick et al. [5]a | 62 M | Brain | SR, RT, chemo | No treatment | 12 M | 1 M | 13 M |
Wick et al. [5]a | 76 M | Brain | SR | No treatment | 3 Y | 0 M | 36 M |
Goepfert et al. [18]b | ? | Brain | ? | ? | ? | ? | ? |
Grosh et al. [17]a | 57 F | Brain | SR | WBRT, chemo | 2 M | 12 M | 14 M |
Grosh et al. [17]a | 56 M | Brain | SR | WBRT, chemo | ≥21 M | ? | ? |
Hitchcock et al. [16]a | 52 M | Brain | SR | WBRT, chemo | 3 M | 9 M | 12 M |
Knox et al. [14]a | 75 F | Brain | SR, RT, HT | WBRT | 4 Y | ? | ? |
Knox et al. [14] | 60 M | Leptomeninges | SR, RT, chemo | WBRT, IT chemo | 10 M | 14 M | 24 M |
Dudley et al. [36] | 64 M | Leptomeninges | SR, RT, chemo | No treatment | 17 M | 6 days | 17 M |
Alexander et al. [35] | 56 M | Brain | – | Biopsy, Wbrt, chemo | Present at dx | 3 Y | 36 Y |
Wojak and Murali [30] | 78 F | Calvaria, Dura | – | SR, LRT | Present at dx | ≥1 Y | ≥12 M |
Manome et al. [11] | 57 F | Skull Base, Brain | – | RA | Present at dx | ? | ? |
Small et al. [8] | 56 M | Brain | – | Biopsy, WBRT | Present at dx | 22 M | 22 M |
Yiengpruksawan et al. [29]a,b | ? | Brain | ? | ? | ? | ? | ? |
Sharma et al. [9]a | 57 M | Brain | – | WBRT, Chemo | Present at dx | 13 M | 13 M |
Snodgrass et al. [7]a,c | 61 M | Brain, Leptomeninges | SR, chemo | WBRT, IT Chemo | 1 Y | 6 M | 18 M |
Eftekhari et al. [21]a,b | ? | Brain | ? | ? | ? | ? | ? |
Eftekhari et al. [21]a,b | ? | Brain | ? | ? | ? | ? | ? |
Eftekhari et al. [21]a,b | ? | Brain | ? | ? | ? | ? | ? |
Matula et al. [10] | 47 M | Skull Base, Dura, Brain | – | SR, RT, Chemo | Present at dx | 12 M | 12 M |
Straka et al. [6]a | 71 F | Brain | SR, RT | Chemo | 10 M | 2 M | 12 M |
Litofsky et al. [12] | 86 F | Brain | SR | SR, RT | 16 M | ≥8 M | 24 M |
Ikawa et al. [15] | 48 F | Brain | SR, RT | SR, WBRT + boost, chemo | 5 Y | 11 M | 71 M |
Eggers et al. [37] | 69 M | Brain, Leptomeninges | SR, RT, Chemo | WBRT + boost | 17 M | <2 M | 18 M |
Barkdull et al. [34] | 55 M | Calvaria, Dura | – | SR, LRT, Chemo | Present at dx | 10 M | 10 M |
Faye et al. [20]a | 85 M | Calviaria, Dura | SR, RT | Chemo | 1 Y | ? | ? |
Faye et al. [20] | 68 M | Brain, Leptomeninges | SR | SR, RT | 1 Y | 7 M | 19 M |
Chang et al. [32] | 45 M | Leptomeninges | SR, RT, Chemo | IT Chemo, WBRT | 2 Y | ≥3 M | ≥25 M |
De Cicco et al. [38]a | 69 M | Brain | SR, Chemo | No treatment | 22 M | 6 M | 28 M |
Feletti et al. [19] | 65 F | Pituitary | SR | SR, Radiosurgery, Chemo | 3.5 Y | ≥8 M | ≥50 M |
Present series | 75 F | Brain | SR | SR + ICC, WBRT | 1 Y | 7 M | 19 M |
Present series | 77 F | Calviaria, Dura | – | SR | Present at dx | ≥16 M | ≥16 M |
Present series | 51 F | Brain | SR | SR + ICC, WBRT | 4 Y | ≥21 M | ≥69 M |
The Table lists the cases of MCC with metastasis to the CNS or its coverings. SR surgical resection, WBTR whole brain radiotherapy, LRT local radiotherapy, RT radiotherapy NOS, IT intrathecal, ICC intracavitary chemotherapy, RS radiosurgery, HT hyperthermic therapy
aPathology from CNS metastasis not confirmed or of unknown confirmation status
bCase abstracted from large series, individualized data not available
cPatient presented with Lambert-Eaton myasthenic syndrome